

Carmello Carlo-Stella

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8686149/carmello-carlo-stella-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

273
papers

8,352
citations

37
h-index

83
g-index

289
ext. papers

9,491
ext. citations

4.4
avg, IF

5.42
L-index

#	Paper	IF	Citations
273	Expanded circulating hematopoietic stem/progenitor cells as novel cell source for the treatment of TCIRG1 osteopetrosis. <i>Haematologica</i> , 2021 , 106, 74-86	6.6	10
272	Planned Interim Analysis of a Phase 2 Study of Loncastuximab Tesirine Plus Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma (LOTIS-3). <i>Blood</i> , 2021 , 138, 54-54	2.2	1
271	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. <i>Leukemia</i> , 2021 , 35, 2672-2683	2.6	15
270	Nonmyeloablative Conditioning Regimen Including Low-Dose Total Marrow/Lymphoid Irradiation Before Haploidentical Transplantation with Post-Transplantation Cyclophosphamide in Patients with Advanced Lymphoproliferative Diseases. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 492.e1-492.e6		2
269	Multicenter Phase II Study on Haploidentical Bone Marrow Transplantation Using a Reduced-Intensity Conditioning Regimen and Posttransplantation Cyclophosphamide in Patients with Poor-Prognosis Lymphomas. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 328.e1-328.e6		
268	Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , 2021 , 22, 790-800	21.7	56
267	Distinctive Biomarker Features in The Endotheliopathy of COVID-19 and Septic Syndromes. <i>Shock</i> , 2021 ,	3.4	11
266	Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1959-1970	2.2	57
265	Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes. <i>Expert Opinion on Therapeutic Targets</i> , 2021 , 25, 423-433	6.4	2
264	Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2021 , 137, 2634-2645	2.2	44
263	Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome. <i>Bone Marrow Transplantation</i> , 2021 , 56, 883-889	4.4	2
262	Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 1144-1153	8.8	2
261	A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma. <i>Investigational New Drugs</i> , 2021 , 39, 1028-1035	4.3	1
260	Complete remission of follicular lymphoma after SARS-CoV-2 infection: from the "flare phenomenon" to the "abscopal effect". <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 2652-2654	8.8	11
259	COVID-19-induced endotheliitis: emerging evidence and possible therapeutic strategies. <i>British Journal of Haematology</i> , 2021 , 193, 43-51	4.5	20
258	ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2911-2921	4.4	2
257	Recurrence-specific supervised graph clustering for subtyping Hodgkin Lymphoma radiomic phenotypes. <i>Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference</i> , 2021 , 2021, 2155-2158	0.9	0

256	The Many Facets of CD38 in Lymphoma: From Tumor-Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy. <i>Cells</i> , 2020 , 9,	7.9	11
255	Copanlisib for the treatment of adults with relapsed follicular lymphoma. <i>Expert Review of Clinical Pharmacology</i> , 2020 , 13, 813-823	3.8	6
254	FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation-Induced Mitochondrial Oxidative Stress. <i>Cancer Research</i> , 2020 , 80, 2340-2354	10.1	18
253	Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study. <i>HemaSphere</i> , 2020 , 4, e302	0.3	5
252	Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin's lymphoma. Assessment of risk of toxicity and secondary cancer induction. <i>Radiation Oncology</i> , 2020 , 15, 12	4.2	8
251	Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group. <i>Blood</i> , 2020 , 136, 6-8	2.2	1
250	Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2020 , 136, 21-23	2.2	9
249	Methodological framework for radiomics applications in Hodgkin's lymphoma. <i>European Journal of Hybrid Imaging</i> , 2020 , 4, 9	1.7	7
248	Generation of an immunodeficient mouse model of tcirg1-deficient autosomal recessive osteopetrosis. <i>Bone Reports</i> , 2020 , 12, 100242	2.6	3
247	Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide. <i>Cancer Medicine</i> , 2020 , 9, 52-61	4.8	10
246	A First-in-human Study of Tenalisib (RP6530), a Dual PI3K γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 78-86	2	9
245	Nonmyeloablative Conditioning Regimen before T Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Hodgkin and Non-Hodgkin Lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 2299-2305	4.7	2
244	Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients. <i>BMC Cancer</i> , 2020 , 20, 1140	4.8	4
243	Salvage Therapy for Hodgkin's Lymphoma: A Review of Current Regimens and Outcomes. <i>Journal of Blood Medicine</i> , 2020 , 11, 389-403	2.3	2
242	Response to Maccio et al, "Multifactorial pathogenesis of COVID-19-related coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders?". <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 3111-3113	15.4	9
241	CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy. <i>Blood Advances</i> , 2020 , 4, 3850-3852	7.8	24
240	Computed tomography (CT)-derived radiomic features differentiate prevascular mediastinum masses as thymic neoplasms versus lymphomas. <i>Radiologia Medica</i> , 2020 , 125, 951-960	6.5	29
239	Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma. <i>Blood Advances</i> , 2020 , 4, 136-140	7.8	12

238	The new refined minnesota risk score for acute graft-versus-host disease predicts overall survival and non-relapse mortality after T cell-replete haploidentical stem cell transplant with post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2019 , 54, 1164-1167	4.4	3
237	Caspofungin for primary antifungal prophylaxis after T-cell-replete haploidentical stem cell transplantation with post-transplant cyclophosphamide. <i>European Journal of Haematology</i> , 2019 , 102, 357-367	3.8	5
236	ANALYSIS OF EFFICACY AND SAFETY OF LONCASTUXIMAB TESIRINE (ADCT-402) BY DEMOGRAPHIC AND CLINICAL CHARACTERISTICS IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA. <i>Hematological Oncology</i> , 2019 , 37, 93-95	1.3	4
235	Peripheral Blood Stem Cells versus Bone Marrow for T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1810-1817	4.7	10
234	Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 1181-1187	6.1	31
233	MicroRNA-127-3p controls murine hematopoietic stem cell maintenance by limiting differentiation. <i>Haematologica</i> , 2019 , 104, 1744-1755	6.6	7
232	CD20-TCB (RG6026), A NOVEL B1.1 FORMAT T-CELL-ENGAGING BISPECIFIC ANTIBODY, INDUCES COMPLETE REMISSIONS IN RELAPSED/REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA. <i>Hematological Oncology</i> , 2019 , 37, 92-93	1.3	14
231	Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	16
230	Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial. <i>Blood</i> , 2019 , 134, 1584-1584	2.2	19
229	Dose-Adjusted EPOCH and Rituximab (DA-EPOCH-R) Treatment in Dual Expressor Diffuse Large B-Cell and Double/Triple Hit Lymphomas: TP53 Mutations Influence on Clinical Outcome. <i>Blood</i> , 2019 , 134, 4116-4116	2.2	2
228	Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019 , 134, 757-757	2.2	7
227	Longitudinal Assessment of Circulating Tumor Mutational Burden Using a Next-Generation Sequencing Cancer Gene Panel: A Potential Biomarker of Response to Programmed Cell Death 1 (PD-1) Blockade in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2019 ,	2.2	3
226	CMV-Seropositive Recipients Are at Higher Risk of CMV Reactivation and NRM after Haploidentical-SCT with PT-Cy. <i>Blood</i> , 2019 , 134, 4484-4484	2.2	
225	Non-Myeloablative Conditioning Regimen before T-Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Lymphoma. <i>Blood</i> , 2019 , 134, 4614-4614	2.2	
224	DOSE DENSE ABVD (DD-ABVD) AS FIRST LINE THERAPY IN EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA (HD): RESULTS OF A PHASE II, PROSPECTIVE STUDY BY FONDAZIONE ITALIANA LINFOMI. <i>Hematological Oncology</i> , 2019 , 37, 291-292	1.3	
223	A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2019 , 25, 6986-6994	12.9	49
222	Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3K/Inhibitor RP6530. <i>Clinical Cancer Research</i> , 2019 , 25, 1098-1112	12.9	35
221	A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogeneic stem cell transplantation from a HLA identical sibling. <i>Transplant Infectious Disease</i> , 2018 , 20, e12906	2.7	2

220	Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. <i>Blood</i> , 2018 , 131, 2413-2425	2.2	122
219	Tandem autologous-haploidentical transplantation is a feasible and effective program for refractory Hodgkin lymphoma. <i>Bone Marrow Transplantation</i> , 2018 , 53, 366-370	4.4	1
218	Are EBV-related and EBV-unrelated Hodgkin lymphomas different with regard to susceptibility to checkpoint blockade?. <i>Blood</i> , 2018 , 132, 17-22	2.2	25
217	CD20-Tcb (RG6026), a Novel "2:1" Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Phase I First in Human Trial. <i>Blood</i> , 2018 , 132, 226-226	2.2	18
216	T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 627-632	4.7	32
215	Vascular amounts and dispersion of caliber-classified vessels as key parameters to quantitate 3D micro-angioarchitectures in multiple myeloma experimental tumors. <i>Scientific Reports</i> , 2018 , 8, 17520	4.9	5
214	Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. <i>Blood</i> , 2017 , 129, 1380-1388	2.2	167
213	Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma. <i>Bone Marrow Transplantation</i> , 2017 , 52, 683-688	4.4	32
212	Estrogen receptor β ligand inhibits Hodgkin lymphoma growth by inducing autophagy. <i>Oncotarget</i> , 2017 , 8, 8522-8535	3.3	26
211	Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. <i>Nature Communications</i> , 2017 , 8, 593	17.4	104
210	SAFETY AND CLINICAL ACTIVITY OF RP6530, A DUAL PI3K/ γ INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES: FINAL ANALYSIS OF A PHASE 1 MULTI-CENTER STUDY. <i>Hematological Oncology</i> , 2017 , 35, 263-263	1.3	4
209	Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma. <i>Haematologica</i> , 2017 , 102, 1931-1935	6.6	7
208	The novel PI3K- β inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest. <i>Leukemia</i> , 2016 , 30, 2402-2405	10.7	12
207	Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation. <i>Scientific Reports</i> , 2016 , 6, 35745	4.9	12
206	Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2016 , 51, 1644-1646	4.4	3
205	Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2016 , 51, 462-5	4.4	4
204	T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes. <i>Bone Marrow Transplantation</i> , 2016 , 51, 194-8	4.4	16
203	Clinical Activity and Safety of RP6530, a Dual PI3K/ γ Inhibitor, in Patients with Advanced Hematologic Malignancies: Final Analysis of a Phase 1 Multicenter Study. <i>Blood</i> , 2016 , 128, 3011-3011	2.2	3

202	Treatment of Hodgkin Lymphoma Xenografts with the Novel PI3K Inhibitor RP6530 Suppresses M2 Macrophage Polarization and Results in Potent Antitumor and Antiangiogenic Effects. <i>Blood</i> , 2016 , 128, 45-45	2.2	3
201	Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3293-9	2.2	66
200	Desensitization with plasma exchange in a patient with human leukocyte antigen donor-specific antibodies before T-cell-replete haploidentical transplantation. <i>Transfusion</i> , 2016 , 56, 1096-1100	2.9	7
199	The patient's CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2016 , 51, 1134-6	4.4	17
198	Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis. <i>Transplant Infectious Disease</i> , 2015 , 17, 242-9	2.7	96
197	Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers. <i>Oncologist</i> , 2015 , 20, 323-8	5.7	25
196	Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation. <i>Blood</i> , 2015 , 125, 2855-64	2.2	100
195	Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma. <i>Biomarkers in Medicine</i> , 2015 , 9, 807-17	2.3	8
194	B-cell reconstitution recapitulates B-cell lymphopoiesis following haploidentical BM transplantation and post-transplant CY. <i>Bone Marrow Transplantation</i> , 2015 , 50, 317-9	4.4	8
193	YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation. <i>International Journal of Cancer</i> , 2015 , 136, 299-309	7.5	26
192	High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study. <i>Annals of Oncology</i> , 2015 , 26, 167-172	10.3	15
191	Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment. <i>Journal of Pathology</i> , 2015 , 237, 4-13	9.4	28
190	Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. <i>Blood</i> , 2015 , 125, 1061-72	2.2	206
189	Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients. <i>Haematologica</i> , 2015 , 100, e423-7	6.6	5
188	Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2015 , 7, e2015015	3.2	10
187	Inflammation and lymphoma: therapeutic implications 2015 , 128-140		
186	High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant. <i>Bone Marrow Transplantation</i> , 2015 , 50, 499-504	4.4	8
185	Synergistic Induction of Cell Death in Hodgkin Lymphoma Cells By the Novel PI3K Inhibitor RP6530 Combined with Brentuximab Vedotin (SGN-35) through Inhibition of Tumor Angiogenesis. <i>Blood</i> , 2015 , 126, 1561-1561	2.2	

184	Predictors of CD34+ cell mobilization and collection in adult men with germ cell tumors: implications for the salvage treatment strategy. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 196-202.e1	3.3	2
183	BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts. <i>Leukemia</i> , 2014 , 28, 1861-71	10.7	35
182	The role of inflammation in lymphoma. <i>Advances in Experimental Medicine and Biology</i> , 2014 , 816, 315-333.6		18
181	Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis. <i>Bone Marrow Transplantation</i> , 2014 , 49, 485-91	4.4	10
180	Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas. <i>Bone Marrow Transplantation</i> , 2014 , 49, 1475-80	4.4	38
179	Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor. <i>Leukemia and Lymphoma</i> , 2014 , 55, 331-6	1.9	24
178	Autophagy as a pathogenic mechanism and drug target in lymphoproliferative disorders. <i>FASEB Journal</i> , 2014 , 28, 524-35	0.9	20
177	Role of alpha-synuclein in autophagy modulation of primary human T lymphocytes. <i>Cell Death and Disease</i> , 2014 , 5, e1265	9.8	33
176	Plerixafor 'on demand': results of a strategy based on peripheral blood CD34+ cells in lymphoma patients at first or subsequent mobilization with chemotherapy+G-CSF. <i>Bone Marrow Transplantation</i> , 2014 , 49, 453-5	4.4	8
175	Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma. <i>Cell Death and Disease</i> , 2014 , 5, e1434	9.8	9
174	Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases. <i>Clinical Cancer Research</i> , 2014 , 20, 5641-51	12.9	28
173	Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi. <i>British Journal of Haematology</i> , 2014 , 166, 140-2	4.5	27
172	Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 724-9	4.7	120
171	Constitutive localization of DR4 in lipid rafts is mandatory for TRAIL-induced apoptosis in B-cell hematologic malignancies. <i>Cell Death and Disease</i> , 2013 , 4, e863	9.8	22
170	Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34(+) cells. <i>Angiogenesis</i> , 2013 , 16, 707-22	10.6	5
169	Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2974-6	2.2	11
168	Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts. <i>Leukemia</i> , 2013 , 27, 1677-87	10.7	22
167	(3)D [corrected] quantification of tumor vasculature in lymphoma xenografts in NOD/SCID mice allows to detect differences among vascular-targeted therapies. <i>PLoS ONE</i> , 2013 , 8, e59691	3.7	9

166	Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells. <i>PLoS ONE</i> , 2013 , 8, e61603	3.7	29
165	Phase II study of sorafenib in patients with relapsed or refractory lymphoma. <i>British Journal of Haematology</i> , 2012 , 158, 108-19	4.5	33
164	Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: evidence for premature aging of the myeloid compartment. <i>Mechanisms of Ageing and Development</i> , 2012 , 133, 479-88	5.6	9
163	The strange case of the lost NRAS mutation in a child with juvenile myelomonocytic leukemia. <i>Pediatric Blood and Cancer</i> , 2012 , 59, 580-2	3	2
162	Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways. <i>Clinical Cancer Research</i> , 2012 , 18, 3316-27	12.9	26
161	Detection of minimal residual disease in hematopoietic progenitor cell harvests: lack of predictive value of peripheral blood and bone marrow analysis in mantle cell and indolent lymphoma. <i>American Journal of Blood Research</i> , 2012 , 2, 105-12	1.6	
160	Dual Targeted Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Patients with Relapsed/Refractory Lymphomas: Final Results of a Phase II Trial. <i>Blood</i> , 2012 , 120, 3679-3679	2.2	5
159	Bendamustine for Relapsed/Refractory Classical Hodgkin Lymphoma After High Dose Chemotherapy and or Allogeneic Transplant: A Study of Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2012 , 120, 3652-3652	2.2	
158	Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target. <i>Blood</i> , 2011 , 118, 4421-30	2.2	28
157	Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis. <i>Investigational New Drugs</i> , 2011 , 29, 1264-75	4.3	28
156	Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia. <i>Cancer</i> , 2011 , 117, 5074-84	6.4	21
155	Safety, Tolerability and Activity of Ofatumumab, Bendamustine and Dexamethasone Combination As First-Line Treatment of Mantle-Cell Lymphoma in the Elderly: A Multicenter Study. <i>Blood</i> , 2011 , 118, 1647-1647	2.2	6
154	Phosphorylation Levels of Extracellular-Signal Regulated Kinase (ERK) and AKT in Circulating Lymphocytes Predict Response to Targeted Therapy with Kinase Inhibitors in Refractory/Relapsed Hodgkin Lymphoma Patients. <i>Blood</i> , 2011 , 118, 3705-3705	2.2	
153	Preclinical Rationale for the Use of the Combined Treatment with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Hodgkin Lymphoma. <i>Blood</i> , 2011 , 118, 1653-1653	2.2	
152	Comparative assessment of telomere length before and after hematopoietic SCT: role of grafted cells in determining post-transplant telomere status. <i>Bone Marrow Transplantation</i> , 2010 , 45, 505-12	4.4	12
151	Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. <i>Cancer Research</i> , 2010 , 70, 9062-72	10.1	114
150	Efficacy and safety of high-dose chemotherapy with in vivo purged auto-SCT in relapsed follicular lymphoma: long-term follow-up. <i>Bone Marrow Transplantation</i> , 2010 , 45, 1119-20	4.4	8
149	Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience. <i>Leukemia and Lymphoma</i> , 2010 , 51, 1251-9	1.9	29

148	Human CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand target both tumor cells and tumor vasculature. <i>Blood</i> , 2010 , 115, 2231-40	2.2	30
147	Radioimmunotherapy and secondary leukemia: a case report. <i>Leukemia Research</i> , 2010 , 34, e1-4	2.7	3
146	Clinical Activity and Safety of the Combined Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib In Heavily Pretreated Patients with Relapsed/Refractory Lymphomas: Preliminary Results of a Phase II Trial. <i>Blood</i> , 2010 , 116, 2861-2861	2.2	
145	Severe Telomeric Erosion In Ph-Negative Hematopoiesis After Successful CML Treatment: Association with Acquired Cytogenetic Lesions and Hematological Toxicity.. <i>Blood</i> , 2010 , 116, 3375-3375 ^{2,2}		
144	Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009 , 36, 1745-57	8.8	16
143	Germ-line mutation of the NRAS gene may be responsible for the development of juvenile myelomonocytic leukaemia. <i>British Journal of Haematology</i> , 2009 , 147, 706-9	4.5	40
142	A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments. <i>Laboratory Investigation</i> , 2009 , 89, 1063-70	5.9	11
141	High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen. <i>Bone Marrow Transplantation</i> , 2009 , 43, 509-11	4.4	25
140	Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. <i>Blood</i> , 2009 , 113, 4771-9	2.2	64
139	Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. <i>Blood</i> , 2009 , 113, 18-27	2.2	91
138	Preliminary Results of a Phase II Trial with the Multikinase Inhibitor Sorafenib in Heavily Pretreated Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL).. <i>Blood</i> , 2009 , 114, 1658-1658	2.2	4
137	High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5175-82	2.2	60
136	The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells. <i>Haematologica</i> , 2008 , 93, 1523-34	6.6	46
135	Phase II Trial of Combination of the Histone Deacetylase Inhibitor ITF2357 and Meclorothamine Demonstrates Clinical Activity and Safety in Heavily Pretreated Patients with Relapsed/Refractory Hodgkin Lymphoma (HL). <i>Blood</i> , 2008 , 112, 2586-2586	2.2	3
134	Anticancer cell therapy with TRAIL-armed CD34+ progenitor cells. <i>Advances in Experimental Medicine and Biology</i> , 2008 , 610, 100-11	3.6	2
133	Targeting TRAIL agonistic receptors for cancer therapy. <i>Clinical Cancer Research</i> , 2007 , 13, 2313-7	12.9	64
132	Long-term lymphoma survivors following high-dose chemotherapy and autograft: evidence of permanent telomere shortening in myeloid cells, associated with marked reduction of bone marrow hematopoietic stem cell reservoir. <i>Experimental Hematology</i> , 2007 , 35, 673-81	3.1	25
131	Highly efficient gene transfer into mobilized CD34+ hematopoietic cells using serotype-5 adenoviral vectors and BoosterExpress Reagent. <i>Experimental Hematology</i> , 2007 , 35, 888-97	3.1	5

130	Placental growth factor-1 potentiates hematopoietic progenitor cell mobilization induced by granulocyte colony-stimulating factor in mice and nonhuman primates. <i>Stem Cells</i> , 2007 , 25, 252-61	5.8	12
129	Forced expression of RDH10 gene retards growth of HepG2 cells. <i>Cancer Biology and Therapy</i> , 2007 , 6, 238-44	4.6	12
128	IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3. <i>Cancer Research</i> , 2007 , 67, 3269-75	10.1	16
127	Human CD34+ Cells Expressing Membrane-Bound Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Exert a Potent Anti-Lymphoma Effects by Targeting Tumor Vasculature.. <i>Blood</i> , 2007 , 110, 527-527	2.2	
126	CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice. <i>Experimental Hematology</i> , 2006 , 34, 721-7	3.1	24
125	The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined immunodeficient mice. <i>Cancer Research</i> , 2006 , 66, 1799-808	10.1	37
124	Antitumor activity of human CD34+ cells expressing membrane-bound tumor necrosis factor-related apoptosis-inducing ligand. <i>Human Gene Therapy</i> , 2006 , 17, 1225-40	4.8	31
123	Skewed T-cell differentiation in patients with indolent non-Hodgkin lymphoma reversed by ex vivo T-cell culture with gammac cytokines. <i>Blood</i> , 2006 , 107, 602-9	2.2	14
122	Two Phase I Open-Label Studies of the Fully Human HLA-DR-Specific IgG4 Monoclonal Antibody 1D09C3 in Patients with Relapsed and/or Refractory B-Cell Lymphoproliferative Neoplasias on a Weekly and Bi-Weekly Dosing Scheme.. <i>Blood</i> , 2006 , 108, 2730-2730	2.2	1
121	High-Dose Myeloablative Zevalin Radioimmunotherapy with Tandem Stem-Cell Autografting Has Promising Activity, Minimal Toxicity and Full Feasibility in an Outpatient Setting.. <i>Blood</i> , 2006 , 108, 3047-3047	2.2	8
120	Antitumor Activity of Human CD34+Cells Expressing Membrane-Bound Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand. <i>Human Gene Therapy</i> , 2006 , 061115111121001	4.8	
119	Interferon γ Enhances the Anti-Myeloma Activity of the Fully Human Anti-HLA-DR Monoclonal Antibody 1D09C3.. <i>Blood</i> , 2006 , 108, 656-656	2.2	
118	Topical prophylaxis of conjunctivitis induced by high-dose cytosine arabinoside. <i>Haematologica</i> , 2006 , 91, 255-7	6.6	12
117	Biology and clinical applications of marrow mesenchymal stem cells. <i>Pathologie Et Biologie</i> , 2005 , 53, 162-4		7
116	Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF. <i>Leukemia</i> , 2005 , 19, 644-51	10.7	26
115	Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed. <i>Experimental Hematology</i> , 2005 , 33, 920-7	3.1	35
114	Genetic idiotypic and tumor cell-based vaccine strategies for indolent non Hodgkin's lymphoma. <i>Current Gene Therapy</i> , 2005 , 5, 511-21	4.3	5
113	High-Dose Myeloablative Zevalin Radioimmunotherapy with Tandem Stem-Cell Autografting Has Minimal Toxicity and Full Feasibility in an Outpatient Setting.. <i>Blood</i> , 2005 , 106, 2737-2737	2.2	3

112	Specific histone patterns and acetylase/deacetylase activity at the breakpoint-cluster region of the human MLL gene. <i>Cancer Research</i> , 2004 , 64, 2656-62	10.1	18
111	Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma. <i>Clinical Cancer Research</i> , 2004 , 10, 5381-90	12.9	76
110	High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults. <i>British Journal of Haematology</i> , 2004 , 126, 815-20	4.5	29
109	Mobilization of primitive and committed hematopoietic progenitors in nonhuman primates treated with defibrotide and recombinant human granulocyte colony-stimulating factor. <i>Experimental Hematology</i> , 2004 , 32, 68-75	3.1	7
108	Age- and irradiation-associated loss of bone marrow hematopoietic function in mice is reversed by recombinant human growth hormone. <i>Experimental Hematology</i> , 2004 , 32, 171-8	3.1	40
107	Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers. <i>Blood</i> , 2004 , 103, 3287-95	2.2	44
106	Primary Plasma Cells Expressing CD52 Are Efficiently Targeted In Vivo by Alemtuzumab.. <i>Blood</i> , 2004 , 104, 3460-3460	2.2	
105	In Vitro and In Vivo Anti-Lymphoma Activity of the Anti-HLA-DR Monoclonal Antibody 1D09C3.. <i>Blood</i> , 2004 , 104, 3285-3285	2.2	
104	Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). <i>Blood</i> , 2003 , 102, 749-55	2.2	172
103	Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts. <i>Leukemia</i> , 2003 , 17, 1783-93	10.7	74
102	Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34(+) cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial. <i>Human Gene Therapy</i> , 2003 , 14, 1347-60	4.8	20
101	Dendritic cell viability is decreased after phagocytosis of apoptotic tumor cells induced by staurosporine or vaccinia virus infection. <i>Haematologica</i> , 2003 , 88, 1396-404	6.6	9
100	Bleomycin genotoxicity and amifostine (WR-2721) cell protection in normal leukocytes vs. K562 tumoral cells. <i>Biochemical Pharmacology</i> , 2002 , 63, 967-75	6	29
99	Identical rearrangement of immunoglobulin heavy chain gene in neoplastic Langerhans cells and B-lymphocytes: evidence for a common precursor. <i>Leukemia Research</i> , 2002 , 26, 1131-3	2.7	33
98	Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. <i>Blood</i> , 2002 , 100, 1104-5	2.2	53
97	Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. <i>Blood</i> , 2002 , 99, 3838-43	2.2	2600
96	Defibrotide in combination with granulocyte colony-stimulating factor significantly enhances the mobilization of primitive and committed peripheral blood progenitor cells in mice. <i>Cancer Research</i> , 2002 , 62, 6152-7	10.1	17
95	Expression and activation of SHC/MAP kinase pathway in primary acute myeloid leukemia blasts. <i>The Hematology Journal</i> , 2001 , 2, 70-80		12

94	Expression and activation of SHC/MAP kinase pathway in primary acute myeloid leukemia blasts. <i>The Hematology Journal</i> , 2001 , 2, 70-80		6
93	T-lymphocyte function after retroviral-mediated thymidine kinase gene transfer and G418 selection. <i>Cancer Gene Therapy</i> , 2000 , 7, 920-6	5.4	14
92	Amifostine (WR-2721) selective protection against melphalan genotoxicity. <i>Leukemia</i> , 2000 , 14, 1642-51	10.7	22
91	Large-scale feasibility of gene transduction into human CD34+ cell-derived dendritic cells by adenoviral/polycation complex. <i>British Journal of Haematology</i> , 2000 , 111, 344-350	4.5	
90	Transforming growth factor beta3 inhibits chronic myelogenous leukemia hematopoiesis by inducing Fas-independent apoptosis. <i>Experimental Hematology</i> , 2000 , 28, 775-83	3.1	6
89	Peripheral blood progenitor cell mobilization in healthy donors receiving recombinant human granulocyte colony-stimulating factor. <i>Experimental Hematology</i> , 2000 , 28, 216-24	3.1	15
88	Limited engraftment capacity of bone marrow-derived mesenchymal cells following T-cell-depleted hematopoietic stem cell transplantation. <i>Blood</i> , 2000 , 96, 3637-3643	2.2	102
87	Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. <i>Journal of Clinical Oncology</i> , 2000 , 18, 1360-77	2.2	265
86	Limited engraftment capacity of bone marrow-derived mesenchymal cells following T-cell-depleted hematopoietic stem cell transplantation. <i>Blood</i> , 2000 , 96, 3637-3643	2.2	1
85	Large-scale feasibility of gene transduction into human CD34+ cell-derived dendritic cells by adenoviral/polycation complex. <i>British Journal of Haematology</i> , 2000 , 111, 344-50	4.5	16
84	Selective expression and constitutive phosphorylation of SHC proteins [corrected] in the CD34+ fraction of chronic myelogenous leukemias. <i>Cancer Research</i> , 2000 , 60, 728-32	10.1	19
83	Limited engraftment capacity of bone marrow-derived mesenchymal cells following T-cell-depleted hematopoietic stem cell transplantation. <i>Blood</i> , 2000 , 96, 3637-43	2.2	27
82	Effects of the Tyrosine Kinase Inhibitor AG957 and an Anti-Fas Receptor Antibody on CD34+ Chronic Myelogenous Leukemia Progenitor Cells. <i>Blood</i> , 1999 , 93, 3973-3982	2.2	41
81	Recombinant adenoviral vector-lipofectAMINE complex for gene transduction into human T lymphocytes. <i>Human Gene Therapy</i> , 1999 , 10, 1875-84	4.8	16
80	Primitive hematopoietic progenitors within mobilized blood are spared by uncontrolled rate freezing. <i>Bone Marrow Transplantation</i> , 1999 , 23, 497-503	4.4	25
79	Chronic myeloid leukemia in first chronic phase not responding to alpha-interferon: outcome and prognostic factors after autologous transplantation. EBMT Working Party on Chronic Leukemias. <i>Bone Marrow Transplantation</i> , 1999 , 24, 259-64	4.4	7
78	Immune reconstitution after in utero bone marrow transplantation in a fetus with severe combined immunodeficiency with natural killer cells. <i>Transplantation Proceedings</i> , 1999 , 31, 2581	1.1	23
77	DNA damage by tobacco smoke and some antitubercular drugs evaluated using the Comet assay. <i>Toxicology Letters</i> , 1999 , 108, 267-76	4.4	29

76	Effects of the Tyrosine Kinase Inhibitor AG957 and an Anti-Fas Receptor Antibody on CD34+ Chronic Myelogenous Leukemia Progenitor Cells. <i>Blood</i> , 1999 , 93, 3973-3982	2.2	1
75	New reciprocal translocation t(5;10)(q33;q22) associated with atypical chronic myeloid leukemia. <i>Haematologica</i> , 1999 , 84, 369-72	6.6	14
74	Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells. <i>Blood</i> , 1999 , 93, 3973-82	2.2	2
73	Therapy of molecular relapse in acute promyelocytic leukemia. <i>Blood</i> , 1999 , 94, 2225-9	2.2	36
72	Induction of apoptosis by arachidonic acid in chronic myeloid leukemia cells. <i>Cancer Research</i> , 1999 , 59, 5047-53	10.1	50
71	Cell therapy: achievements and perspectives. <i>Haematologica</i> , 1999 , 84, 1110-49	6.6	51
70	CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF. <i>Bone Marrow Transplantation</i> , 1998 , 21, 561-8	4.4	31
69	Reverse transcription polymerase chain reaction is a reliable assay for detecting leukemic colonies generated by chronic myelogenous leukemia cells. <i>Leukemia</i> , 1998 , 12, 434-40	10.7	7
68	In Vitro Manipulation of Peripheral Blood Progenitor Cell Collections. <i>International Journal of Artificial Organs</i> , 1998 , 21, 1-10	1.9	2
67	Shc Overexpression Induces Selective Hypersensitivity to GM-CSF and Prevents Apoptosis of the GM-CSF-Dependent Acute Myelogenous Leukemia Cell Line GF-D8. <i>Hamatologie Und Bluttransfusion</i> , 1998 , 363-368		
66	Inactivation of bone marrow cultures and K562 leukaemic cell line by Mbsbauer effect. <i>Anticancer Research</i> , 1998 , 18, 419-23	2.3	0
65	The parallel between CD45 expression and extra-medullary evolution in aggressive myeloma with high serum lactate dehydrogenase. <i>Haematologica</i> , 1998 , 83, 276-9	6.6	
64	Ex vivo expansion of hematopoietic cells and their clinical use. <i>Haematologica</i> , 1998 , 83, 824-48	6.6	13
63	High-dose therapy in acute leukemia. <i>Leukemia and Lymphoma</i> , 1997 , 26 Suppl 1, 61-7	1.9	
62	Biologic and phenotypic analysis of early hematopoietic progenitor cells in umbilical cord blood. <i>Leukemia</i> , 1997 , 11, 2143-9	10.7	21
61	Clonogenic capacity and ex vivo expansion potential of umbilical cord blood progenitor cells are not impaired by cryopreservation. <i>Bone Marrow Transplantation</i> , 1997 , 19, 1079-84	4.4	25
60	Effect of chemotherapy for acute myelogenous leukemia on hematopoietic and fibroblast marrow progenitors. <i>Bone Marrow Transplantation</i> , 1997 , 20, 465-71	4.4	70
59	Retroviral transfer of herpes simplex virus-thymidine kinase and beta-galactosidase genes into U937 cells with bicistronic vector. <i>Leukemia Research</i> , 1997 , 21, 951-9	2.7	9

58	In vitro growth of mobilized peripheral blood progenitor cells is significantly enhanced by stem cell factor. <i>Stem Cells</i> , 1997 , 15, 207-13	5.8	3
57	Stem cell manipulation: why and how performing peripheral blood progenitor cell purging. <i>Critical Reviews in Oncology/Hematology</i> , 1997 , 26, 101-15	7	7
56	Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein. <i>Blood</i> , 1996 , 88, 3091-3100	2.2	46
55	Density separation and cryopreservation of umbilical cord blood cells: evaluation of recovery in short-and long-term cultures. <i>Acta Haematologica</i> , 1996 , 95, 171-5	2.7	12
54	Effect of the protein tyrosine kinase inhibitor genistein on normal and leukaemic haemopoietic progenitor cells. <i>British Journal of Haematology</i> , 1996 , 93, 551-7	4.5	17
53	BCL2 oncogene protein expression in human hematopoietic precursors during fetal life. <i>Experimental Hematology</i> , 1996 , 24, 459-65	3.1	7
52	Response to cyclosporin A and recombinant human erythropoietin in a case of B cell chronic lymphocytic leukemia and pure red cell aplasia. <i>Leukemia</i> , 1996 , 10, 1400-1	10.7	4
51	Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein. <i>Blood</i> , 1996 , 88, 3091-100	2.2	4
50	Stem cells and stem cell transplantation. <i>Haematologica</i> , 1996 , 81, 573-87	6.6	4
49	Density separation of umbilical cord blood and recovery of hemopoietic progenitor cells: implications for cord blood banking. <i>Stem Cells</i> , 1995 , 13, 533-40	5.8	23
48	Arachidonic acid induces c-jun gene expression in stromal cells stimulated by interleukin-1 and tumor necrosis factor-alpha: evidence for a tyrosine-kinase-dependent process. <i>Blood</i> , 1995 , 86, 2967-2975	2.2	37
47	Oligodeoxynucleotides antisense to c-abl specifically inhibit entry into S-phase of CD34+ hematopoietic cells and their differentiation to granulocyte-macrophage progenitors. <i>Blood</i> , 1995 , 86, 3387-3393	2.2	30
46	Techniques for detection of minimal residual disease. <i>Leukemia and Lymphoma</i> , 1995 , 18 Suppl 1, 75-80	1.9	8
45	Natural killer cell regeneration after transplantation with mafosfamide purged autologous bone marrow. <i>Bone Marrow Transplantation</i> , 1995 , 16, 95-101	4.4	7
44	Stem cell purging: an intriguing dilemma. <i>Experimental Hematology</i> , 1995 , 23, 296-302	3.1	12
43	Arachidonic acid induces c-jun gene expression in stromal cells stimulated by interleukin-1 and tumor necrosis factor-alpha: evidence for a tyrosine-kinase-dependent process. <i>Blood</i> , 1995 , 86, 2967-2975	2.2	3
42	Umbilical cord blood as a source of hematopoietic stem cells: from research to clinical application. <i>Haematologica</i> , 1995 , 80, 473-9	6.6	17
41	Identification of Philadelphia-negative granulocyte-macrophage colony- forming units generated by stroma-adherent cells from chronic myelogenous leukemia patients. <i>Blood</i> , 1994 , 83, 1373-1380	2.2	31

40	Identification of Philadelphia-negative granulocyte-macrophage colony-forming units generated by stroma-adherent cells from chronic myelogenous leukemia patients. <i>Blood</i> , 1994 , 83, 1373-80	2.2	
39	Selection of Philadelphia-negative progenitors from chronic myelogenous leukemia. <i>Bone Marrow Transplantation</i> , 1994 , 14 Suppl 3, S45-8	4.4	
38	Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide. <i>Bone Marrow Transplantation</i> , 1994 , 14, 425-32	4.4	25
37	Identification of Philadelphia-negative granulocyte-macrophage colony-forming units generated by stroma-adherent cells from chronic myelogenous leukemia patients. <i>Blood</i> , 1994 , 83, 1373-1380	2.2	1
36	Effect of recombinant human stem cell factor on mafosfamide-treated bone marrow clonogenic cells. <i>Stem Cells</i> , 1993 , 11 Suppl 2, 170-4	5.8	2
35	Fractionation of chronic myelogenous leukemia marrow cells by stroma adherence: implications for marrow purging. <i>Leukemia and Lymphoma</i> , 1993 , 11 Suppl 1, 109-12	1.9	3
34	Biology and Clinical Applications of Longterm Bone Marrow Cultures. <i>International Journal of Artificial Organs</i> , 1993 , 16, 76-79	1.9	3
33	Acquired cyclic thrombocytopenia-thrombocytosis with periodic defect of platelet function. <i>British Journal of Haematology</i> , 1993 , 85, 718-22	4.5	16
32	Autologous transplantation for chronic myelogenous leukemia with mafosfamide-treated marrow. <i>Stem Cells</i> , 1993 , 11 Suppl 3, 25-30	5.8	2
31	Biological and chemical selection of Ph-negative clones. <i>Stem Cells</i> , 1993 , 11 Suppl 3, 77-82	5.8	
30	Biology and clinical applications of long-term bone marrow cultures. <i>International Journal of Artificial Organs</i> , 1993 , 16 Suppl 5, 76-9	1.9	1
29	Counterflow centrifugal elutriation: present and future. <i>Bone Marrow Transplantation</i> , 1993 , 12, 105-8	4.4	8
28	Purging the bone marrow in non-Hodgkin's lymphomas. Is there any evidence of its value?. <i>Leukemia and Lymphoma</i> , 1992 , 7 Suppl, 7-10	1.9	
27	Use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with lymphoid malignancies transplanted with unpurged or adjusted-dose mafosfamide-purged autologous marrow. <i>Blood</i> , 1992 , 80, 2412-2418	2.2	13
26	Effects of Mössbauer radiation on bone marrow cultures. <i>Hyperfine Interactions</i> , 1992 , 71, 1267-1270	0.8	1
25	Gamma-rays from Mössbauer sources: a low-dose approach to cancer therapy. <i>Nuovo Cimento Della Societa Italiana Di Fisica D - Condensed Matter, Atomic, Molecular and Chemical Physics, Biophysics</i> , 1992 , 14, 351-358		3
24	Use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with lymphoid malignancies transplanted with unpurged or adjusted-dose mafosfamide-purged autologous marrow. <i>Blood</i> , 1992 , 80, 2412-8	2.2	2
23	Autologous bone marrow transplantation in acute myelogenous leukemia. <i>Leukemia</i> , 1992 , 6, 1101-6	10.7	12

22	Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation. <i>Experimental Hematology</i> , 1992 , 20, 328-33	3.1	13
21	Use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with lymphoid malignancies transplanted with unpurged or adjusted-dose mafosfamide-purged autologous marrow. <i>Blood</i> , 1992 , 80, 2412-2418	2.2	
20	Establishment and characterization of a B-cell line derived from a patient with a myelodysplastic syndrome which expresses myelomonocytic and lymphoid markers. <i>British Journal of Haematology</i> , 1991 , 78, 167-72	4.5	10
19	In vitro marrow purging in chronic myelogenous leukemia: effect of mafosfamide and recombinant granulocyte-macrophage colony-stimulating factor. <i>Bone Marrow Transplantation</i> , 1991 , 8, 265-73	4.4	26
18	Effect of recombinant human granulocyte-macrophage colony-stimulating factor (rh GM-CSF) in patients with lymphoid malignancies receiving unpurged or mafosfamide-purged autografts. <i>Behring Institute Mitteilungen</i> , 1991 , 69-74		
17	Human peripheral blood mononuclear cell subfractionation using counterflow centrifugation elutriation. <i>Haematologica</i> , 1991 , 76, 89-93	6.6	2
16	Tumor necrosis factor alpha modulates the messenger RNA expression of hematopoietic growth factor genes in fresh blast cells from patients with acute myeloblastic leukemia. <i>Leukemia</i> , 1991 , 5, 886-91	10.7	5
15	Hematopoietic growth factors: in vitro and in vivo studies in bone marrow transplantation. <i>International Journal of Cell Cloning</i> , 1990 , 8 Suppl 1, 270-7; discussion 277-8		1
14	Growth of CD34+ acute myeloblastic leukemia colony-forming cells in response to recombinant hematopoietic growth factors. <i>Leukemia</i> , 1990 , 4, 561-6	10.7	21
13	Tumor necrosis factor alpha down-regulates c-myc mRNA expression and induces in vitro monocytic differentiation in fresh blast cells from patients with acute myeloblastic leukemia. <i>Leukemia</i> , 1990 , 4, 426-30	10.7	8
12	In vitro growth of bone marrow-derived multipotent and lineage-restricted hematopoietic progenitor cells in myelodysplastic syndromes. <i>Haematologica</i> , 1989 , 74, 181-6	6.6	2
11	In vitro and in vivo effects of recombinant interferon gamma on the growth of hematopoietic progenitor cells from patients with myelodysplastic syndrome. <i>Haematologica</i> , 1989 , 74, 435-40	6.6	5
10	Growth of human hematopoietic colonies from patients with myelodysplastic syndromes in response to recombinant human granulocyte-macrophage colony-stimulating factor. <i>Leukemia</i> , 1989 , 3, 363-6	10.7	19
9	Effects of desferrioxamine on normal and leukemic human hematopoietic cell growth: in vitro and in vivo studies. <i>Leukemia</i> , 1989 , 3, 104-7	10.7	30
8	Effects of recombinant human H-subunit and L-subunit ferritins on in vitro growth of human granulocyte-monocyte progenitors. <i>British Journal of Haematology</i> , 1988 , 68, 367-72	4.5	12
7	Synergistic antiproliferative effect of recombinant interferon-gamma with recombinant interferon-alpha on chronic myelogenous leukemia hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM). <i>Blood</i> , 1988 , 72, 1293-1299	2.2	41
6	Synergistic antiproliferative effect of recombinant interferon-gamma with recombinant interferon-alpha on chronic myelogenous leukemia hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM). <i>Blood</i> , 1988 , 72, 1293-9	2.2	4
5	Synergistic antiproliferative effect of recombinant interferon-gamma with recombinant interferon-alpha on chronic myelogenous leukemia hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM). <i>Blood</i> , 1988 , 72, 1293-1299	2.2	

4	Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia. <i>Blood</i> , 1987 , 70, 1014-9	2.2	17
3	Defective in vitro growth of the hemopoietic progenitor cells in the acquired immunodeficiency syndrome. <i>Journal of Clinical Investigation</i> , 1987 , 80, 286-93	15.9	128
2	Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia. <i>Blood</i> , 1987 , 70, 1014-1019	2.2	66
1	Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia. <i>Blood</i> , 1987 , 70, 1014-1019	2.2	3